AGT and diabetic kidney disease: Subsequently, large randomized clinical trials, have further supported the importance of RAAS blockade in preventing kidney failure in DKD, including the Reduction of Endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan (RENAAL) and Irbesartan in Diabetic Nephropathy Trial (IDNT).